

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

PROTOCOL CODE: GIGAVFFOXP

Page 1 of 3

DOCTOR'S ORDERS	Ht	cm Wt	kg BS/	Am²	
REMINDER: Please ensure drug all	ergies and previous	bleomycin are do	cumented on	the Allergy & Alert Form	
DATE:	To be given:		Cycle(s	) #:	
Date of Previous Cycle:					
☐ Delay treatment week(s) ☐ CBC & Diff day of treatment					
Day 1: May proceed with doses as written if within 72 hours <b>ANC</b> <u>greater than or equal to</u> 1.2 x 10 <sup>9</sup> /L, platelets <u>greater than or equal to</u> 75 x 10 <sup>9</sup> /L, ALT <u>less than or equal to</u> 3 times the upper limit of normal, <u>total bilirubin less than or equal to</u> 1.5 times the upper limit of normal <u>and less than or equal to</u> 1.5 x baseline.					
Days 15 and 29: May proceed with doses as written if within 72 hours <u>ANC greater than or equal</u> to 1.2 x 10 <sup>9</sup> /L, Platelets greater than or equal to 75 x 10 <sup>9</sup> /L.					
Dose modification for: Hemato  Proceed with treatment based on bl		r Toxicity			
PREMEDICATIONS: Patient to tak	•	armacist to confirm	1	_	
ondansetron 8 mg PO prior to treatm				•	
dexamethasone ☐ 8 mg or ☐ 12 mg (select one) PO prior to treatment (omit if below dexamethasone IV premedication ordered)					
For prior pembrolizumab infusion reaction:  diphenhydrAMINE 50 mg PO 30 minutes prior to pembrolizumab acetaminophen 325 to 975 mg PO 30 minutes prior to pembrolizumab hydrocortisone 25 mg IV 30 minutes prior to pembrolizumab					
For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2): 45 minutes prior to oxaliplatin: <b>dexamethasone 20 mg</b> IV in 50 mL NS over 15 minutes 30 minutes prior to oxaliplatin: <b>diphenhydrAMINE 50 mg</b> IV in NS 50 mL over 15 minutes and <b>famotidine 20 mg</b> IV in NS 100 mL over 15 minutes (Y-site compatible)					
For patients with prior pembrolizumab and oxaliplatin reaction, administer oxaliplatin premedications prior to pembrolizumab					
NO ice chips					
Other:					
** Have Hypersensitivity Reaction Tray & Protocol Available**					
TREATMENT: (Note – contin	ued over 2 pages	5)			
pembrolizumab line to be primed with NS; oxaliplatin and leucovorin lines to be primed with D5W					
pembrolizumab 4 mg/kg x kg = mg (max. 400 mg)  IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter on Day 1					
oxaliplatin 85 mg/m² x BSA =mg  ☐ Dose Modification:mg/m² x BSA =mg  IV in 250 to 500 mL D5W over 2 hours* on Days 1, 15 and 29. Flush line with D5W pre and post dose.					
**CONTINUED ON PAGE 2**					
DOCTOR'S SIGNATURE:				SIGNATURE:	
				UC:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: GIGAVFFOXP

Page 2 of 3

DATE:						
TREATMENT: (Continued)						
leucovorin (select one if fluorouracil IV push ordered; optional if fluorouracil IV push omitted)						
☐ leucovorin 400 mg/m² x BSA = mg IV in 250 mL D5W over 2 hours* on Days 1, 15 and 29 *oxaliplatin and leucovorin may be infused over same two hour period by using a Y-site connector placed immediately before the injection site						
OR						
leucovorin 20 mg/m² x BSA = mg IV push on Days 1, 15 and 29						
flourouracil						
IV push (optional)						
☐ fluorouracil 400 mg/m² x BSA = mg ☐ Dose Modification:mg/m² x BSA =mg IV push on Days 1, 15 and 29, THEN						
Infusion (required)						
fluorouracil 2400 mg/m² x BSA = mg**  Dose Modification: mg/m² x BSA = mg**  IV over 46 hours in D5W to a total volume of 230 mL by continuous infusion at 5 mL/h via Baxter LV5 INFUSOR on Days 1, 15 and 29  ** For 3000 to 5500 mg dose select INFUSOR per dose range below (doses outside dose banding range are prepared as ordered):						
Dose Banding Range	Dose Band INFUSOR (mg)	Pharmacist In	itial and Date			
Less than 3000 mg	Pharmacy to mix specific dose					
3000 to 3400 mg	3200 mg					
3401 to 3800 mg	3600 mg					
3801 to 4200 mg	4000 mg					
4201 to 4600 mg	4400 mg					
4601 to 5000 mg	4800 mg					
5001 to 5500 mg	5250 mg					
Greater than 5500 mg	Pharmacy to mix specific dose					
DOCTOR'S SIGNATURE:			SIGNATURE:			
			UC:			



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: GIGAVFFOXP

Page 3 of 3

DATE:	
RETURN APPOINTMENT ORDERS	
Return in <u>six</u> weeks for Doctor and for Cycle Book <u>treatment</u> on Days 1, 15, and 29	
Return in weeks for Doctor assessment	
Last Cycle. Return in week(s)	
CBC & Diff, creatinine, ALT, total bilirubin, sodium, potassium, TSH prior to Day 1 of each cycle	
CBC & Diff, creatinine, total bilirubin, ALT on Days 15 and 29 of each cycle	
If clinically indicated:   CEA CA 19-9 ECG chest x-ray	
☐ free T3 and free T4 ☐ lipase ☐ morning serum cortisol ☐ random glucose	
☐ alkaline phosphatase ☐ albumin ☐ GGT ☐ creatine kinase ☐ troponin	
☐ serum ACTH levels ☐ testosterone ☐ estradiol ☐ FSH ☐ LH	
☐ serum HCG or ☐ urine HCG – required for woman of childbearing potential	
☐ INR weekly ☐ INR prior to each cycle	
☐ Book for PICC assessment / insertion per Centre process	
☐ Book for IVAD insertion per Centre process	
☐ Weekly nursing assessment	
☐ Other consults:	
☐ See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: